A.A. Kamalov - Dr.Sc. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Director of University Clinic of MSU of M.V. Lomonosov; Head of the Department of Urology and Andrology, FFM MSU of M.V. Lomonosov. E-mail: armais.kamalov@rambler.ru Z.Sh. Pavlova - Ph.D. (Med.), Doctor-endocrinologist, University Clinic of MSU of M.V. Lomonosov. E-mail: zukhra73@gmail.com A.V. Gostry - Doctor, General Practice Recovery, Functional and Anti-aging Medicine, Institute of Preventive Medicine. E-mail: agostry@gmail.com D.A. Ohobotov - Ph.D. (Med.), Doctor-urologist, University Clinic of MSU of M.V. Lomonosov. E-mail: 14072003m@gmail.com R.P. Vasilevsky - Doctor Urologist-Andrologist, District Urologist of South West Administrative District, Head of Department of Budgetary Public Health Facility Municipal Policlinic № 134 Moscow State Depart-ment. E-mail: urolog-rv@yandex.ru

There are numerous questions concerning an etiology and pathogenesis of the disease despite the success achieved in diagnostics and cancer therapy of a prostatic gland. Relevance of this problem steadily grows in parallel with the same progressive increase in number of the men having this disease against increase in life expectancy. There is no acute and clear understanding of hormones interaction among themselves and their impacts on these or those receptors in prostatic gland, in other words system endocrine and local paracrine effects, so that it is the main problem in pathogenesis of prostate cancer and finding of effective methods of treatment of this disease. Decisive data have appeared confirming the dominating role of metabolites of estrogen in difficult and mul-tiple-factor pathogenesis of prostate cancer. Besides, the new approach which was outlined in un-derstanding of process of the inflammation arising at development of obesity, metabolic syndrome and including oncology disease processes, make perspective searches of the most effective methods of treatment and prevention of all these threatening diseases. The developed diagnostics methods focused on getting the objective data promoting preventive influence and giving the chance to prevention of development of prostate cancer. It is appropriate approach directed, first of all, to prevention of this threatening disease.

 

1. Risbridger G.P., Ellem S.J., McPherson S.J. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling // Journal of Molecular Endocrinology. 2007. V. 39. P. 183-188.
2. Rohrmann S., Nelson W.G., Rifai N. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans //J. Clin. Endocrinol. Metab.2007. V. 92. № 7. R. 2519-2525.
3. Dedov I.I., Melnichenko G.A., Fadeev V.V. «EHndokinologija», 2000.
4. James C. Roberts, M.D. FACC, FAARFM Estrogen Metabolismwithin the framework of Bioidentical Ovarian Hormone Replacement Therapy (HRT)// Methyl Cycle Nutrigenomics. 2012. R. 33.
5. Nelles J.L., Hu Wen-Yang, Prins G.S. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab. Author manuscript; available in PMC. 2012. Mar. 1.2011 May; V. 6(3). P. 437-451.
6. Ellem S.J., Risbridger G.P. Aromatase and regulating the estrogen: androgen ratio in the prostate gland // Journal of Steroid Biochemistry and Molecular Biology. 2009. V. 188 (4-5). P. 246-251.
7. Prins G.S., Birch L., Couse J.F. et al. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies alpha ERKO and beta ERKO mice // Cancer. Res. 2001. V. 61. P. 6089-6097.
8. Nelson W.G., De Marzo A.M., De Weese T.L. et al. The role of inflammation in the pathogenesis of prostate cancer // J. Urol. 2004. V. 172. P. S6-SI1, discussion interfering with the dynamics of estrogen receptor regulated transcription.
9. Muti P., Bradlow H.L., Micheli A., Krogh V., Freudenheim J.L., Schunemann H.J., Stanulla M., Yang J., Sepkovic D.W., Trevisan M., Berrino F. Estrogen metabolism and risk of breast cancer: a prospective study of the : 16 alpha hydrox estrone ratio in premenopausal and postmenopausal women // Epidemiology. 2000. Nov. V. 11(6). P. 635-406.
10. PrimakA.V.Metabolizmehstrogenovuzhenshhin. Obshhie predstavlenija i klinicheskaja praktika // EHsteticheskaja medicina. 2006. T. V. № 2.
11. Rogan E.G., Badawi A.F., Devanesan P.D., Meza J.L., Edney J.A., West W.W., Higginbotham S.M., Cavalieri E.L. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer // Carcinogenesis (England). 2003. Apr. V. 4. № 24. P. 697-702.
12. Liehr J.G., Ricci M.J. 4-Hydroxylation of estrogens as marker of human mammary tumors // Proc. Natl. Acad. Sci. USA. 1996. Apr. 16. V. 93. № 8. P. 3294-3296.
13. Utsunomiya H., Ito K., Suzuki T., Kitamura T., Kaneko C., Nakata T., Niikura H., Okamura K., Yaegashi N., Sasano H. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma // Clin. Cancer. Res. Sep. 1 2004. № 10 (17). P. 5850-5656.
14. Guillemette C., Belanger A., Lepine J. Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview // Breast. Cancer. Res. 2004. V. 6. № 6. P. 246-254.
15. Genova Diagnostics·A.L. Peace-Brewer, D(ABMLI), Lab. Director CLIA Lic. № 34D0655571. Medicare Lic. № 34-8475.
16. Bradlow H.L., Davis D.L., Lin G,. Sepkovich D., Tiwari R. Effects of pesticides on the ratio of 16/2-hydroxyestrone: a biologic marker of breast cancer risk // Environ Health Perspect. 1995. V. 103. (Suppl.7). R. 147-150.
17. Bradlow H.L., Davis D.L., Lin G. et al. Effects of pesticides on the ratio of 16α/2- hydroxyestrone: a biological marker of breast cancer risk // Environ Health Perspect. 1995. V.103 (Suppl 7). P. 147-150.
18. Teas J.,Cunningham J.E.,Fowke J.H.,Nitcheva D.,Kanwat C.P.,Boulware R.J.,Sepkovic D.W.,Hurley T.G.,Hebert J.R. Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina // Cancer Detect Prev.2005.V. 29.№ 6. P. 494-500.
19. Muti P.,Westerlind K.,Wu T.,Grimaldi T.,De Berry J. 3rd,Schünemann H.,Freudenheim J.L.,Hill H.,Carruba G.,Bradlow L. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States // Cancer Causes Control.2002. Dec. 13(10). P. 947-955.
20. Barba M.1.,Yang L.,Schünemann H.J.,Sperati F.,Grioni S.,Stranges S.,Westerlind K.C.,Blandino G.,Gallucci M.,Lauria R.,Malorni L.,Muti P. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis //J. Exp. Clin. Cancer. Res.2009 Oct. 8. № 8. P. 135. doi: 10.1186. P. 1756-9966-28-135.
21. Santen R.J., Petroni G.R., Fisch M.J., Myers C.E., Theodorescu D., Cohen R.B. Use of the aromatase inhibitor anastrosole in the treatment of patients with advanced prostate carcinoma // Cancer. 2001. V. 92. P. 2095-2101.
22. Kruit W.H., Stoter G., Klijn J.G. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate specific antigen response in metabolic prostate cancer refractory to standard endocrine therapy // Anticancer Drugs. 2004. V. 15. P. 843-847.
23. AshrafjanL.A.,KiseljovV.I.Opukholi reproduktivnykh organov (ehtiologija i patogenez). M. 2007.
24. Ioannides C. Effect of diet and nutrition on the expression of cytochromes P450. Xenobiotica 1999. V. 29(2). P. 109-154.
25. Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations // Scand. J. Clin. Lab. Invest. 1990. V. 50(S201). P. 3-23.
26. Cavalieri E.,Rogan E.G. The molecular etiology and prevention of estrogen-initiated cancers: Ockham\'s Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity // Mol. Aspects. Med. 2014. Apr; V. 36. P. 1-55. doi: 10.1016/j.mam.2013.08.002. Epub 2013 Aug 30.
27. Cavalieri E.L.,Rogan E.G. Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer // J. Steroid. Biochem. Mol. Biol.2011. V. 125(3-5). P. 169-80. doi: 10.1016/j.jsbmb. 2011.03.008. E. pub 2011. Mar. 21.
28. Yang L.,Gaikwad N.W.,Meza J.,Cavalieri E.L.,Muti P.,Trock B.,Rogan E.G.Novel biomarkers for risk of prostate cancer: results from a case-control study // Prostate.2009. Jan. 1. V. 69(1). P. 41-48. doi: 10.1002/ pros.20850.
29. Zhu X., Leav I., Leung Y.K., Wu M., Liu Q., Gao Y., McNeal J.E., Ho S.M. Dynamic regulation of estrogen receptor β-expression by DNA methylation during prostate cancer development and metastasis // American Journal of Pathology. 2009. V. 164. P. 2003-2012.
30. SHvarc V.JA. Vospalenie zhirovojj tkani(chast 1). Morfologicheskie i funkcionalnye projavlenija // Problemy ehndokrinologii. 2009. T.55. №4. S.44-49.
31. SHvarc V.JA. ZHirovaja tkan, kak ehndokrinologicheskijj organ // Problemy ehndokrinologii. 2009. T.55. №1. S.38-44.
32. Kunsch C., Medford R.M. Oxidative stress as a regulation of gene expression in the vasculature // Cire. Res. 1999. V. 85. P. 753-766.